Awardee OrganizationVETERANS HEALTH ADMINISTRATION
Description
Abstract Text
A hallmark of chronic kidney disease (CKD) is advancing tubulointerstitial (TI) fibrosis. While new mechanisms
of fibrosis have been uncovered in recent decades, effective treatment to directly halt or reverse this process
remains elusive. Our group has a long-standing interest in defining how extracellular matrix (ECM) receptors
such as integrins and their binding partners regulate kidney development and response to injury. Among the
integrin binding partners, we focus on the integrin linked kinase (ILK); pinch; α-parvin complex of scaffold
proteins, also known as the IPP complex. We recently uncovered a novel modality to interfere with integrin
dependent signaling pathways mediated by the IPP complex that may represent a new strategy to treat and
prevent TI fibrosis and ultimately CKD.
Integrins are transmembrane receptors composed of non-covalently bound α and β subunits. β1 is the most
abundantly expressed subunit in the kidney and can bind 12 different α subunits. The β1 cytoplasmic tail
functions by binding multiple cytoplasmic proteins which regulate integrin-mediated signaling and cytoskeleton
modulation. The IPP complex is a major scaffolding hub that binds the integrin β1 cytoplasmic tail and its key
function is to bundle actin filaments, thereby transmitting mechanical signals between integrins and the actin
cytoskeleton. A normal actin cytoskeleton is required for most cell functions necessary for embryonic
development and recovery of tissue from injury. ILK is the major scaffold protein that brings the IPP complex
together; however, the α and β parvins are the major IPP complex proteins that regulate the actin cytoskeleton.
We have preliminary evidence that α-parvin is required for normal kidney development and repair after injury.
Deletion of α-parvin in mice at the initiation of the kidney collecting system (E10.5) causes severely dysmorphic
kidneys with excessive basolateral F-actin. We also provide evidence that deleting α-parvin in the fully developed
kidney collecting system (E 18.5) results in excessive tubular injury following a unilateral ureteric obstruction
(UUO) model. Mice carrying a mutant ILK unable to bind to α-parvin (K-to-M mutation in a.a. 220: ILK-K220M
mice) in the developing collecting system develop normally and wild-type mice treated with the small molecule
Csbl-1 (that interferes with the ILK-α-parvin interaction) have decreased renal fibrosis following UUO. These
data strongly suggest that α-parvin performs multiple cellular functions that are independent of its interactions
with ILK and paradoxically disrupting ILK binding to α-parvin improves the response of the kidney to injury.
Finally, we have evidence that α-parvin-null collecting duct (CD) cells have excessive F-actin formation,
increased cell adhesion, spreading and migration as well as a profound increase in activated RhoA and Cdc42.
Based on these data, we hypothesize that α-parvin-mediated regulation of actin dynamics via Rho-GTPase
signaling promotes kidney tubule development, homeostasis, and recovery from injury. This hypothesis
will be tested in the following 2 aims.
Aim 1. Determine the role of α-parvin in kidney tubule development and injury. We will test the hypothesis
that α-parvin-mediated actin filament bundling is required for normal kidney tubule development and
protection from injury.
Aim 2. Determine the mechanisms whereby α-parvin regulates actin-bundling dependent epithelial cell
function. We will test the hypothesis that α-parvin-mediated inhibition of RhoA and Cdc42 activity
promotes cofilin-mediated actin turnover dependent epithelial cell polarity and proliferation that is
required for normal tubule formation and repair.
Public Health Relevance Statement
Narrative
We anticipate that this study will generate novel insights into the mechanisms whereby the integrin linked kinase
(ILK), Pinch and parvin (IPP) complex regulates the response of kidney tubules to injury and fibrosis. We will
also test the ability of novel ILK inhibitors to decrease the amount of injury and fibrosis in mouse models of kidney
injury. This knowledge may result in novel therapeutics being developed to protect the kidney from chronic injury.
No Sub Projects information available for 2I01BX002196-09A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2I01BX002196-09A1
Patents
No Patents information available for 2I01BX002196-09A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2I01BX002196-09A1
Clinical Studies
No Clinical Studies information available for 2I01BX002196-09A1
News and More
Related News Releases
No news release information available for 2I01BX002196-09A1
History
No Historical information available for 2I01BX002196-09A1
Similar Projects
No Similar Projects information available for 2I01BX002196-09A1